Related Experiment Video
Updated: May 28, 2025
10:27
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.2K
Targeting CDK4/6 in breast cancer
Anusha Shanabag1, Jessica Armand1,2, Eugene Son1
1Department of Pathology and Cell Biology, Columbia University, New York, NY, USA.
Experimental & Molecular Medicine
|February 10, 2025
Summary
Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors are vital for treating hormone receptor-positive breast cancer. Understanding and overcoming drug resistance are crucial for improving patient outcomes and enhancing therapeutic efficacy.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Overactivation of cyclin-dependent kinases 4 and 6 (CDK4/6) drives breast cancer progression.
- CDK4/6 inhibitors have revolutionized hormone receptor-positive breast cancer treatment by targeting cell cycle progression.
Purpose of the Study:
- To review the molecular mechanisms of cell cycle regulation in breast cancer.
- To examine the clinical applications of CDK4/6 inhibitors.
- To elucidate mechanisms of resistance to CDK4/6 inhibitors and discuss strategies to overcome them.
Main Methods:
- Literature review of molecular mechanisms.
- Analysis of clinical trial data for CDK4/6 inhibitors.
- Exploration of resistance pathways and emerging biomarkers.
Main Results:
- Dysregulated cell cycle machinery, especially CDK4/6, is central to breast cancer.
- CDK4/6 inhibitors show significant clinical success but face resistance challenges.
- Lack of predictive biomarkers hinders personalized treatment strategies.
Conclusions:
- Further research into resistance mechanisms is essential for optimizing CDK4/6 inhibitor therapy.
- Identifying predictive biomarkers will guide treatment decisions and improve patient outcomes.
- Developing strategies to overcome resistance is key to enhancing therapeutic efficacy in breast cancer.
Related Concept Videos
02:34Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
02:15M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
7.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K
03:03mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K